Dasatinib is an oral multi-BCR/ABL and Src family tyrosine kinase inhibitor approved for the use in patients with chronic myelogenous leukemia (CML) after imatinib treatment [39, 40] and in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) [41]. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.